Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study.
Floris T M BoschErzsébet Horváth-PuhóSuzanne C CannegieterNick Van EsHenrik Toft SorensenPublished in: PLoS medicine (2024)
In this population based cohort study, factor Xa inhibitor use was not associated with an overall lower incidence of cancer or cancer-related mortality when compared to dabigatran. We did observe an increase in all-cause mortality in the factor Xa inhibitor cohort.